New drug approved for HIV treatment Pharmacy Europe, UK - Nov 26, 2008 ... said: "New, effective and well-tolerated treatment options are critical for treatment-experienced persons living with HIV infection. ...
FDA Safety Changes: Viread and Sustiva Medscape (registration) - Nov 5, 2008 Efavirenz tablets and capsules are indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Drug Development for Neglected Diseases ? The Trouble with FDA... New England Journal of Medicine (subscription), MA - Nov 5, 2008 ... that treat conditions for which no adequate therapy exists, such as certain types of cancer and infection with the human immunodeficiency virus (HIV). ...
FDA Safety Changes: Nasacort AQ, Reyataz, Zemuron Medscape (registration) - Nov 19, 2008 Atazanavir is a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. On August 28, the FDA...
FDA Approvals: Toviaz, Prezista, Astepro Medscape (registration) - Nov 13, 2008 Describe an expanded indication for ritonavir-boosted darunavir in the treatment of HIV-1 infection. Identify the potential benefits associated with a new ...
FDA Panel Recommends Stronger Derma Filler Warnings InjuryBoard.com, FL - Nov 19, 2008 Of those, 823 were classified as injuries, including bleeding, infection, lumps or bumps in the face and in some rare cases, facial disfigurement. ...
Source: Google News
Recent News and Articles on the Keywords: 0.17 + web + 328 Related to the article below (Last Update: 8/7/2008)
JouleTrack-A Web Based Tool for Software Energy Profiling - A Sinha, AP Chandrakasan - Proceedings of the 38th Design Automation Conference (DAC … - doi.ieeecomputersociety.org Page 1. JouleTrack - A Web Based Tool for Software Energy Profiling ... 0.15 0.155 0.16
0.165 0.17 0.175 0.18 0.185 0.19 0.195 0.2 Instruction Modes Current (A) ...
Regulation of Lake Primary Productivity by Food Web Structure - SR Carpenter, JF Kitchell, JR Hodgson, PA Cochran, … - Ecology, 1987 - JSTOR ...0.17 0.16 0.22 1 0.24 0.38 Tuesday 1984 0.21 0.17 0.21 0.06 1 ... Manipulation of the
pelagic food web by stocking with pre- dacious ... Oecologia (Berlin) 60:328-332. ...
[PDF]Effective Prediction of Web-user Accesses: A Data Mining Approach - A Nanopoulos, D Katsaros, Y Manolopoulos - WEBKDD, 2001 - skyblue.csd.auth.gr Page 1. Effective Prediction of Web-user Accesses: A Data Mining ... The problem of
predicting web-user accesses has re- cently attracted significant attention. ...
Research Findings of a Library Skills Instruction Web Course - LB Alexander, RC Smith - portal: Libraries and the Academy, 2001 - muse.jhu.edu ... 309-328. Copyright ? 2001 by The Johns Hopkins University Press, Baltimore, MD 21218.
ResearchFindings of a Library Skills Instruction Web Course ...
Analysis of a Lake Superior coastal food web with stable isotope techniques - JR Keough, ME Sierszen, CA Hagley - Limnology and Oceanography, 1996 - JSTOR ... 44.7 Regression coefficient/3 (slope) 1.33 +0.16 1.48 +0.17 R2 0.44 ... sludge and
eutrophication in the sediments and food web of estuarine ... BioScience 38} 328-336 ...
Web Relocation and Habitat Selection in Desert Widow Spider - Y Lubin, S Ellner, M Kotzman - Ecology, 1993 - JSTOR ... 0.45* -0.17 Larger webs ... Eberhard, WG 1971. The ecology of the web of Uloborus diversus
(Araneae: Uloboridae). Oecologia 6:328-342. Ellnet, S., and LA Real. ...
Source: Google Scholar
HIV-1 infection: FDA has approved Atripla, an once-a-day three-drug combination
The FDA ( Food and Drug Administration ) has approved Atripla, a fixed-dose combination of three widely-used antiretroviral drugs, in a single tablet taken once a day, alone or in combination with other antiretroviral products for the treatment of HIV-1 infection in adults.
Atripla, the first one-pill, once-a-day product to treat HIV/AIDS, combines the active ingredients of Efavirenz ( Sustiva ), Emtricitabine ( Emtriva ) and Tenofovir disoproxil ( Viread ).
" The approval of Atripla simplifies the treatment regimen for HIV-1 infected adults, and will potentially improve the ability of patients to adhere to treatment resulting in long-term effective control of HIV-1. This offers a particularly important advantage for patients in many countries that are most affected by the AIDS epidemic and will also have a major impact in the U.S.," said Andrew C. von Eschenbach, the Acting Commissioner of Food and Drugs.
FDA approved Sustiva in 1998, Viread in 2001 and Emtriva in 2003.
The safety and effectiveness of the combination of these three drugs were shown in a 48 week clinical study with 244 HIV-1 infected adults receiving the drugs contained in Atripla.
In this trial, 80 percent of the participants achieved a marked reduction of the human immunodeficiency virus and a substantial increase in the number of healthy CD4 cells.
The labeling of Atripla includes a boxed warning that the drug's use can cause lactic acidosis.
In patients with chronic hepatitis B infection, the discontinuation of the treatment with Atripla ( which is not approved for this use ) can result in severe flare-ups of hepatitis B infection.
Other potential serious adverse events reported for the use of Atripla's ingredients include serious liver toxicity, renal impairment and severe depression.
The most common adverse events experienced by participants in the combination trial included headache, dizziness, abdominal pain, nausea, vomiting and rash.
There are more than a million people living with HIV and AIDS in the United States today and 40,000 new cases are reported each year.
Currently, there are 28 FDA approved products in the United States used in the treatment of HIV infection.
